Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Global, regional, & national burden of rheumatic heart disease, 1990-2015

We estimated the global disease prevalence of and mortality due to rheumatic heart disease over a 25-year period

Research

The 5 × 5 path toward rheumatic heart disease control: Outcomes from the third rheumatic heart disease forum

This editorial viewpoint regarding the outcomes from the third global Rheumatic Heart Disease Forum intends to carry forward dialogue & engage new...

Research

Rheumatic heart disease among adults in a mining community of Papua, Indonesia: findings from an occupational cohort

To describe the pattern of RHD occurrence in a sample of presenting cases from an occupational cohort in Papua Province, Indonesia.

News & Events

Trans-Tasman partnership to tackle rheumatic heart disease

Researchers at The Kids Research Institute Australia have begun a comprehensive research project into vaccines aimed at tackling rheumatic fever.

People

Professor Jonathan Carapetis AM

Institute Director; Head, Strep A Translation; Co-Founder of REACH

Glenn Pearson's dream - improving Aboriginal child health

As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story

Research

Morbidity of Scabies in Resource-Limited Countries: Rheumatic Heart Disease (RHD) and Post-Streptococcal Glomerulonephritis (APSGN)

Scabies is one of the world’s most prevalent diseases, with approximately 147 million cases at any one time and an estimated annual incidence of 455 million new episodes. Although Group A streptococcal (GAS) pharyngitis has long been implicated in the pathogenesis of acute rheumatic fever (ARF) and subsequent rheumatic heart disease (RHD), impetigo caused by GAS has recently been postulated as a link between scabies and the pathogenesis of ARF.

Research

Research opportunities for the primary prevention and management of acute rheumatic fever and rheumatic heart disease: a National Heart, Lung, and Blood Institute workshop report

Primary prevention of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) encompasses the timely diagnosis and adequate treatment of the superficial group A Streptococcus (GAS) infections pharyngitis and impetigo. GAS is the only known inciting agent in the pathophysiology of the disease.

Research

Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease - streptococcal vaccine development: a national heart, lung and blood institute workshop report

Streptococcus pyogenes, also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease.